Yafeng Gao*, Lei Gao**, #, Yan Peng***, Junhong Long**, Miaoyan Yang**
*Department of Pharmacy, The Affiliated Hospital of Yan’an University, 43 North Street, Yan’an, Shaanxi, China 716000 - **Department of Endocrinology, The Second Affiliated Hospital of Xi’an Jiaotong University, 157, Xiwu 5th Road, Xi’an, Shaanxi, China 710004 - ***Department of Oncology, Chang’an Hospital, Chang’an Hospital Xi’an, Shaanxi, China 710000
Purpose: To discuss and investigate the therapeutic effects of combination of linagliptin and metformin on treatment of elderly type 2 diabetes mellitus patients and its influences on serum uric acid, insulin resistance and insulin â cell function.
Methods: Two hundred elderly patients with type 2 diabetes mellitus treated in our hospital from March 2014 to March 2016 were selected as the subjects and randomly divided into two groups, including a control group and an observation group (100 cases each). The patients in the control group were treated with metformin, while the patients in the observation group were treated with the combination of linagliptin and metformin. Before and after treatment, some indexes of the patients in the two groups were observed, including glycated haemoglobin (HbAlc), serum uric acid, fasting plasma glucose (FPG), 2 h postprandial plasma glucose (2hPG), body mass index (BMI), fasting C-peptide, 2 h postprandial C-peptide, fasting insulin (FIns) and 2 h postprandial insulin (2hIns), and insulin resistance indexes (HOMA-IR) were calculated, and the functions of insulin â cells were evaluated (HOMA-â). In addition, the efficiency of clinical treatment, the incidence of hypoglycaemia and the rate of adverse reactions were statistically investigated.
Results: After treatment, the HbAlC, FPG, 2hPG, serum uric acid and BMI of the patients in the two groups were decreased, and there were significant differences (P<0.05). After treatment, the HbAlC, FPG, 2hPG, serum uric acid and BMI of the patients in the observation group were all lower than those in the control group, and there were significant differences (P<0.05). The fasting C-peptide, 2 h postprandial C-peptide, FIns, 2hIns and HOMA-â of the patients in the two groups after treatment were increased, HOMA-IRs were decreased, and there were significant differences (P<0.05). After treatment, the fasting C-peptide, 2 h postprandial C-peptide, FIns, 2hIns and HOMA-â of the patients in the observation group were higher than those in the control group, the HOMA-IRs were lower than the control group, and there were significant differences (P<0.05). The marked effective rate, the effective rate and the total effective rate of the observation group were higher than those of the control group, the ineffective rate was lower than that of the control group, and there were significant differences between the data in the two groups (P<0.05). The rates of adverse reactions in the control group were higher than those in the observation group, and there were significant differences (P<0.05). The total adverse reaction rate in the control group was 26%, the total adverse reaction rate in the observation group was 15%, the total adverse reaction rate in the observation group was lower than that in the control group, and there were significant differences (P<0.05).
Conclusions: Compared with metformin alone, the combination of linagliptin and metformin in the treatment of type 2 diabetes mellitus can achieve a better clinical therapeutic effect, which has high safety, can reduce serum uric acid, recover insulin resistance and insulin â cell function, can be used for the treatment of elderly type 2 diabetes mellitus, and has good clinical treatment significance.
Linagliptin, metformin, elderly type 2 diabetes mellitus.
10.19193/0393-6384_2020_1_66